|
|
|
|
|
Last Trade
|
Last Trade:
$21.00
|
Change:
-1.57 (-6.96%)
|
Trade Time:
Dec 11
|
Market Cap:
$515.06M
|
|
|
|
|
|
|
Description of Business
|
|
We are a late clinical-stage biopharmaceutical company focused on developing and
commercializing novel treatments for gastrointestinal, or GI, diseases. Our
initial product candidate, vonoprazan, is an oral small molecule potassium
competitive acid blocker, or P-CAB. P-CABs are a novel class of medicines that
block acid secretion in the stomach. Vonoprazan has shown rapid, potent, and
durable anti-secretory effects and has demonstrated clinical benefits over
standard of care treatments as a single agent in the treatment of
gastroesophageal reflux disease, or GERD, and in combination with antibiotics
for the treatment of Helicobacter pylori, or H. pylori,infection. Takeda
Pharmaceutical Company Limited, or Takeda, developed vonoprazan and has received
marketing approval in nine countries in Asia and Latin America. Vonoprazan
generated over $500 million in net sales in its fourth full year on the market
since its approval in Japan in late 2014.
|
|
|
|